Kymera Investor Presentation Deck

DL3 and 4 Degradation Profile of IRAK4, Ikaros and Aiolos Consistent with Strong Antitumor Activity in Preclinical Models IRAK4 Ikaros Aiolos Percent Change from Baseline Percent Change from Baseline 150 100 50 0 -50 -100 0 -20- -40 -60 -80 -100 150 100 50 -50 Target Degradation in PBMC by FLOW DL1 DL2 DL3 DL4 0.16 mg/kg 0.32 mg/kg 0.51 mg/kg 0.82 mg/kg Cycle 1 Cycle 2 M -100 T 0 0 T 2 24 Hours T 2 24 Hours 02 24 Hours Note Cycle 1, 72 hours window = +24 hours 72 72 72 T 8 Days 8 15 0 + 15 Days T T 2 Hours - T 24 8 T 15 Days T T 0 2 24 8 Hours 15 Days 8 15 0 2 24 8 15 Days Hours Days KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. Dose Level Cycle 1 DL1 -4% DL2 -28% DL3 ΝΑ DL4 -70% H Dose Cycle 1 Level DL1 -82% D -92% DL3 ΝΑ -89% DL4 Dose Level DL1 DL2 DL3 DL4 Cycle 1 -95% -100% ΝΑ -95% Cycle 2 0 -40% -57% ΝΑ Cycle 2 -89% -95% -96% ΝΑ Cycle 2 - 89% -100% -100% ΝΑ Five patients were treated across DL1-4.** ● 1 each at DL1-3 and 2 at DL4 • PD results on first 4 patients Up to 70% KD of IRAK4 and 96- 100% KD of Ikaros and Aiolos in PBMC at DL1-4 DL3-4 expected to be clinically active doses/profiles. Degradation consistent with target knockdown needed for antitumor responses in preclinical models of MYD88mut DLBCL (slide 36) *These included patients with transformed activated B-cell-like (ABC)-diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, and plasmablastic lymphoma, all of whom were MYD88 wild-type except for one who had a MYD88 gain-of-function mutation. As of the data cut-off date of June 1, 2023. PAGE 39

View entire presentation